Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus MANNITOL 15 W DEXTROSE 5 IN SODIUM CHLORIDE 0 45.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus MANNITOL 15 W DEXTROSE 5 IN SODIUM CHLORIDE 0 45.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Mannitol increases plasma osmolality, drawing water from tissues into the intravascular space via osmotic gradient, thereby reducing intracranial pressure and promoting diuresis. Dextrose provides caloric support. Sodium chloride provides electrolytes.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous: 50 to 100 g (333-667 mL) initially, then 50 g (333 mL) every 4-6 hours to maintain urine output of 30-50 mL/hr. Administer as a 15% solution with dextrose 5% in 0.45% sodium chloride.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Mannitol: 0.5-1.5 hours in normal renal function; prolonged to 24-48 hours in anuria; dextrose: 1-2 hours; negligible for sodium chloride.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal excretion of unchanged mannitol: 80-90% within 24 hours; dextrose is fully metabolized; sodium chloride is renally excreted.
Category C
Category A/B
Electrolyte
Electrolyte